Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...
A few treatments are known to help clear psoriasis symptoms fast, such as Clobex spray, cyclosporine, and Humria. When choosing a psoriasis treatment, however, also consider other factors like side ...
The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Explore more details here.
The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable ...
Limitations of the study include the relatively small sample size for long-term follow-up and the potential for bias ... long-term treatment for patients with moderate to severe plaque psoriasis.” ...